Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Mental Health Strategy 2024-2030

Executive Summary
 
We can all play a role in promoting and safeguarding mental health for all population groups and in supporting individuals going through difficult times. This strategy serves as a seven-year roadmap aimed at guiding the Ministry of Public Health and all relevant stakeholders while mobilizing efforts to improve mental health in Lebanon. In Lebanon, in particular, improving mental health also requires addressing the social, economic, and political factors that negatively impact mental well-being and hinder the recovery process.
 
The strategy was developed using a comprehensive approach to address key issues. First, an assessment of the mental health situation in the country was conducted, including the burden of diseases, needs, and an evaluation of the existing system’s ability to meet these needs. Previous efforts were also reviewed to identify areas that need to be maintained and those requiring improvement. Furthermore, consultations were held with experts and local stakeholders, including individuals with lived experiences, to help set strategic priorities. The strategy was also guided by international frameworks, including World Health Organization (WHO) guidelines and other evidence-based recommendations. Special care was taken to select approaches that are appropriate and adaptable to the local context. Finally, the strategy was published and made available to the public for feedback and revisions.
 
The strategy addresses all fundamental aspects of the mental health system to enhance overall mental well-being and prevent mental disorders, with a focus on the following key areas:
  • Raising awareness about mental health, reducing misconceptions, and implementing evidence-based interventions to prevent mental health issues. This includes emphasizing the importance of addressing political, social, and economic factors that influence mental health.
  • Empowering individuals by providing them with the resources, knowledge, and skills necessary to protect their mental well-being and ensuring access to available services when needed.
  • Ensuring that individuals with mental health disorders can access high-quality care whenever they need it, regardless of their place of residence.
  • Supporting healthcare providers and all professionals in the field by building their capacity based on evidence-based practices and helping them safeguard their own mental health.
  • Preventing and reducing harmful practices that violate human rights and quality standards in the provision of mental health services.
  • Enhancing data availability and conducting valuable research to guide and support efforts to improve mental health across the country.
  • Establishing legal frameworks, policies, and appropriate funding mechanisms to strengthen the mental health system.
  • Integrating the views, perspectives, and preferences of individuals with lived experiences in the design, development, and implementation of services, policies, and practices.
Specific actions have been planned for each of these key areas to ensure the necessary improvements in the country.
 

 
National Mental Health Strategy 2024-2030 (Please click on this link to download the document)
 
Theory of Change Map (Please click on this link to download the document)

Executive Summary (English, French, Arabic) 
 
    ...
    49
    ...
ATC Name B/G Ingredients Dosage Form Price
M01AE17 DEXIREN G Dexketoprofen - 50mg/2ml 50mg/2ml Injectable solution 467,657 L.L
A02BC06 DEXILANT B Dexlansoprazole - 30mg 30mg Capsule, delayed release 1,595,141 L.L
A02BC06 DEXILANT B Dexlansoprazole - 60mg 60mg Capsule, delayed release 2,375,914 L.L
N05CM18 PRECEDEX (DEXMEDETOMIDINE) B Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable solution 19,441,512 L.L
N05CM18 DEXMEDETOMIDINE EVER PHARMA G Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable concentrate for solution 9,340,433 L.L
N05CM18 PROXIDA G Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable concentrate for solution 1,771,184 L.L
N05CM18 DEXMEDETOMIDINE EVER PHARMA G Dexmedetomidine HCl - 400mcg/4ml 400mcg/4ml Injectable concentrate for solution 15,543,897 L.L
A02BC07 DEXPURE B Dexrabeprazole sodium - 10mg 10mg Tablet, enteric coated 517,379 L.L
R05FB02 MUCUS RELIEF DM G Dextromethorphan HBr - 20mg, Guaifenesin - 400mg Tablet 413,903 L.L
R05DA09 DIACOL G Dextromethorphan HBr - 27mg/15ml 27mg/15ml Syrup 517,379 L.L
R05DA20 ALGOMIEL COUGH SYRUP G Dextromethorphan HBr - 5mg, Carbinoxamine maleate - 2mg Syrup 639,925 L.L
R05FB BRONCHOPHANE G Dextrometorphan HBr - 4.58mg/5ml, Diphenydramine HCl - 5mg/5ml, Ephedrine HCl - 7.5mg/5ml, Guaifenesin - 50mg/5ml Syrup 115,570 L.L
B05CX01 7.5% DEXTROSE INJECTION USP G Dextrose monohydrate - 7.5% 7.5g/100ml Injectable solution 202,256 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 10g/100ml 10g/100ml Injectable solution 170,630 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 10g/100ml 10g/100ml Injectable solution 194,211 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 10g/100ml 10g/100ml Injectable solution 219,493 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 10g/100ml 10g/100ml Injectable solution 170,630 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 10g/100ml 10g/100ml Injectable solution 252,820 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 10g/100ml 10g/100ml Injectable solution 284,997 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 10g/100ml 10g/100ml Injectable solution 220,643 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 20g/100ml 20g/100ml Injectable solution 369,209 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 20g/100ml 20g/100ml Injectable solution 807,874 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 30g/100ml 30g/100ml Injectable solution 944,626 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 33g/100ml 33g/100ml Injectable solution 287,295 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 33g/100ml 33g/100ml Injectable solution 312,577 L.L
B05 20 MEQ POTASSIUM OF 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP B Dextrose, H2O - 5%, Sodium chloride - 0.45%, Potassium chloride - 20meq Injectable solution 229,959 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 50g/100ml 50g/100ml Injectable solution 329,815 L.L
B05CX01 ALDEX G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 174,062 L.L
B05CX01 ALDEX G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 174,062 L.L
B05CX01 ALDEX G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 170,630 L.L
    ...
    49
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025